Home › Trials › NCT03661866

Observational study of patients with immune-mediated inflammatory skin conditions

A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions

Observational Target PharmaSolutions, Inc. · NCT03661866

This study is tracking adults and kids with skin conditions like Atopic Dermatitis to see how well their treatments work and to gather important data over time.

Quick facts

Study typeObservational
Enrollment15000 (estimated)
SexAll
SponsorTarget PharmaSolutions, Inc. Industry-sponsored
Locations63 sites (Scottsdale, Arizona and 62 other locations)
Trial IDNCT03661866 on ClinicalTrials.gov

What this trial studies

TARGET-DERM is a longitudinal observational study focusing on adult and pediatric patients being treated for Atopic Dermatitis and other immune-mediated inflammatory skin conditions (IMISC). The study aims to create a research registry that captures real-world data on the safety and effectiveness of current and future therapies in both academic and community settings. Participants will be followed for up to five years in the EU, while those in the US and Canada may consent to indefinite follow-up.

Who should consider this trial

Good fit: Ideal candidates include adults and children diagnosed with Atopic Dermatitis or other IMISC who are receiving dermatologic treatment.

Not a fit: Patients currently participating in interventional studies for IMISC treatment may not benefit from this observational study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term safety and effectiveness of treatments for patients with IMISC.

How similar studies have performed: Other observational studies have shown success in capturing real-world data for similar conditions, indicating that this approach is both viable and valuable.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
* 2. Participant has plans for future visits at the site for continued management of IMISC.

Exclusion Criteria:

* 1. Inability to provide written informed consent/assent.
* 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Where this trial is running

Scottsdale, Arizona and 62 other locations

+13 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Atopic DermatitisAlopecia AreataHidradenitis SuppurativaVitiligoPsoriasisChronic Spontaneous UrticariaIMISCRegistry
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.